TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03044145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cultural Formulation Interview-Engagement Aid (Revised)
Description: The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard mental health treatment at FHMC
Study: NCT01831791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
Study: NCT04987372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The use of multimodal painkillers pre, per and postoperative
Study: NCT04612426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer Interface-Pedaling Training System
Description: The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Traditional Pedaling Training System
Description: The patient will wear the same EEG equipment that will only collect data, but not guide training.
Study: NCT04009148

Intervention type: OTHER
Intervention: CASCADE genetic screening
Description: Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives

Intervention type: OTHER
Intervention: CASCADE genetic screening
Description: Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
Study: NCT04389697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clear fluids and food up to up to 1 hour before the procedure
Description: Clear fluids and food up to up to 1 hour before the start of the procedure
Study: NCT02030626

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: active or placebo rTMS or active or placebo tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active or placebo rTMS or active or placebo tDCS
Study: NCT03246906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study: NCT03915769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
Study: NCT02397317

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction SABR
Description: All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
Study: NCT03442413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-[18F]-FA PET/CT
Description: 2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V. Nicotine
Description: Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
Study: NCT01214746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk 1 time pr day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr day for 5 days
Study: NCT01671969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low calorie diet
Description: medically supervised diet
Study: NCT03679663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of ultrasound to identify pre-puncture site
Study: NCT00734786

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wrinkle cream application
Description: Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
Study: NCT00849264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with endostar
Description: 15mg/d×14d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with CBP and 5-FU
Description: CBP 300mg/d×2d，5-FU 1000mg/d×5d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment with endostar, CBP and 5-FU
Description: CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
Study: NCT04460690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Onsite COVID-19 Detection
Description: saliva assay test for high concentrations of SARS-CoV-2
Study: NCT03445858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Index Site Radiation
Description: Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
Study: NCT01912937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty treatment with the CVI Drug-coated Balloon (DCB)
Description: Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
Study: NCT03428412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM and conventional drug
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo and conventional drug
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Study: NCT04169594

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Gait Analysis with Statistical Parametric Mapping
Description: A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Gait Analysis with Statistical Parametric Mapping
Description: A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
Study: NCT03197337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-test
Description: Pressure will be applied to the posterior fornix using a speculum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-test
Description: Pressure will be applied to the posterior fornix using a speculum.
Study: NCT03246906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT04076397

Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous transplant reinjection
Description: The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days

Intervention type: OTHER
Group type: OTHER
Intervention: desensitization
Description: Patients will have to stimulate the pulp of your finger on a daily basis
Study: NCT04314726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amelogenin
Description: amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
Study: NCT01845402

Intervention type: BIOLOGICAL
Intervention: blood and urine samples
Description: A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
Study: NCT03347357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
Study: NCT00101413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
Study: NCT01140113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Ultrafiltration
Description: After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
Study: NCT00858013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Description: Nateglinide 90\~120mg three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1\~2mg once a day
Study: NCT02399696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care-Brief Mindfulness Program
Description: A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care-Treatment as Usual
Description: Typical VA primary care treatment, including mental health services delivered by primary care staff.
Study: NCT03808883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TGNC Directed Advocacy Meetings
Description: Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Dialogues between TGNC Cohort and Healthcare Participants
Description: Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Dialogues between TGNC Cohort and Healthcare Participants
Description: Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
Study: NCT00158054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced depression care
Description: Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referred depression care
Description: Physician notified of depression symptoms, usual care followed.
Study: NCT04676568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extravesical VVF repair
Description: Both standard transvesical and extravesical approach for VVF repair will be utilised

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extravesical VVF repair
Description: Both standard transvesical and extravesical approach for VVF repair will be utilised
Study: NCT02947217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: 0.5 mL of sterile Saline administered im
Study: NCT02032719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone-assisted health coaching
Description: smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling
Study: NCT01305434

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mulberry leaf extract effect on post prandial blood glucose
Description: Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mulberry leaf extract effect on post prandial blood glucose
Description: Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications.
Study: NCT01586299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg every 8 hours until 24 hours after resolution of fever

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 15 mg/kg every 6 hours until 24 hours after resolution of fever
Study: NCT01434134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Tablet, target dose 100 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, target dose 100 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Tablet, target dose 32 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 32 mg once daily
Study: NCT01505946

Intervention type: OTHER
Intervention: TGA (Thrombin generation Assay)
Description: TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period

Intervention type: OTHER
Intervention: TGA (Thrombin generation Assay)
Description: TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period
Study: NCT01641172

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dexa scan
Description: the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexa scan
Description: the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: audiogram
Description: the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.
Study: NCT04251208

Intervention type: OTHER
Intervention: Observational Study
Description: No intervention will be administered.

Intervention type: OTHER
Intervention: Observational Study
Description: No intervention will be administered.
Study: NCT02712372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension
Study: NCT01641172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: audiogram
Description: the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: measurement of heart rate variability and baroreflex sensitivity
Description: the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.
Study: NCT02712372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4831 placebo
Description: AZD4831 placebo oral suspension
Study: NCT01980342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
Study: NCT00609284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: D-7, D1, D8, D15, D22, D29, D43, D50

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: D-7, D1, D8, D15, D22, D29, D43, D50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, 5FU concomitant
Description: Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 7 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy in 7 weeks
Study: NCT00635518

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ten Steps for Healthy Feeding children programme
Description: Ten Steps for Healthy Feeding children